The Private Equity fund of Gilde Healthcare acquires German medtech company Acti-Med - Gilde Healthcare

The Private Equity fund of Gilde Healthcare acquires German medtech company Acti-Med

April 27, 2021

Investment to support the global expansion of leading manufacturer of precision medical components and devices

Utrecht (the Netherlands) and Freienstau – The Private Equity fund of Gilde Healthcare, a specialist healthcare investor, has acquired Acti-Med, a leading international developer and contract manufacturer of high-quality medical components and devices for the medical and pharmaceutical industries.

Founded in 1997, Germany-based Acti-Med focuses on tailor-made, highly regulated, cannulas and cannula systems for pharmaceutical and medical applications, jointly developed with international Original Equipment Manufacturers (OEMs). Headquartered in Freiensteinau (Germany) and with operations in Kozerkí (Poland), Acti-Med has attracted clients from all around the world by combining the highest development and engineering capabilities, offering superior quality and operational flexibility. Recent expansions into promising adjacent end markets, supported by innovative best-in-class products highlight the company’s ambitions for growth.

Gilde Healthcare will collaborate with Acti-Med to further strengthen and expand its product portfolio in both the Ready for Market and Ready for Clean room segments, as well as further expand its manufacturing and design capacity to serve its increasing demands from its Pharma and Medical Device customers.

Andreas Schwalb, Founder and CEO of Acti-Med added:

“Acti-Med has had a truly exciting journey over the last 24 years and I am proud to look back on how we have grown our company from scratch into a global leader in our field. I would like to thank everyone at Acti-Med for their invaluable contributions. Now is the right time in our development to bring significant new investment and competencies to support our growth. We are pleased to have attracted Gilde Healthcare, who bring deep sector knowledge and a constructive, collaborative mindset. I look forward to working with Gilde Healthcare for Acti-Med’s successful future.”

Rafael Natanek, Partner at Gilde Healthcare, added:

“We are pleased to complete this acquisition of Acti-Med, a highly regarded contract manufacturer of tailor-made cannula and cannula systems with promising growth opportunities. The company has, through its design-skills, high-quality manufacturing, and flexibility to achieve rapid growth. We are excited to be investing in the company’s continued growth and look forward supporting the management as we consider additional options, such as strategic acquisitions.”

The shareholders of Acti-Med have been advised by DZ BANK Corporate Finance as exclusive M&A advisor.

 

Media contacts:
LifeSci Advisors
Frank Schwarz – fschwarz@lifesciadvisors.com / +49 17 26 15 31 60

Gilde Healthcare
Rafael Natanek – natanek@gildehealthcare.com / +31 61 18 44 63 0

About Acti-Med

Acti-Med is one of the leading manufacturers in the field of medical technology. Headquartered in Freiensteinau, Germany Acti-Med’s competence lies in the development and production of cannulas and cannula systems. Acti-Med develops, produces and sells high-quality medical components and devices for medical and pharmaceutical industries. Our customers are located throughout a wide range of industries, including oncology, pain therapy, the pharmaceutical industry and veterinary medicine. www.acti-med.de.

About Gilde Healthcare

Gilde Healthcare is a specialized healthcare investor managing over €1.4 billion across two fund strategies: Private Equity and Venture & Growth. Gilde Healthcare Private Equity participates in profitable European lower mid-market healthcare companies with a prime focus on the Benelux and DACH region. The Private Equity fund targets healthcare providers, suppliers of medical products and service providers in the healthcare market. Gilde Healthcare Venture & Growth invests in medtech, healthtech and therapeutics in Europe and North America.
For more information, visit the company’s website at www.gildehealthcare.com

Gilde Healthcare company Ablative Solutions demonstrates Significant Reduction in Blood Pressure meeting its primary endpoint in Pivotal Trial

Ablative Solutions, Inc., announced that primary trial results from the TARGET BPI Pivotal Trial, evaluating alcohol-mediated renal denervation with the Peregrine SystemTM Kit, were presented as a Late-Breaking Clinical Trial at the American College of...
April 11, 2024

Gilde Healthcare company ProVerum Announces Completion of Enrollment for the ProVIDE Clinical Study for BPH and First-use of its New Flexible, Steerable Delivery System

ProVerum Limited, an Irish medical device company developing a minimally invasive solution to treat benign prostatic hyperplasia (BPH) in the doctor's office, today announced completion of enrollment of the ProVIDE pivotal clinical trial to evaluate...
March 21, 2024

Gilde Healthcare sells RAD-x to a consortium of Swiss Life Asset Managers and Vesper Infrastructure Fund I

Gilde Healthcare’s Private Equity Fund (“Gilde Healthcare”), a specialized healthcare investor, has reached a binding agreement to sell its majority stake in RAD-x to a consortium of Swiss Life Asset Managers and Vesper Next Generation...
March 18, 2024